Our greatest strength is our integrated approach. In our research we bring to bear the best of both conventional and innovative drug discovery techniques.

  • We pioneer fragment- and structure-based methods in the context of a full drug discovery capability with six development candidates since 2009
  • The majority of our scientific team has worked together for more than a decade - allowing us to build a strong, interdisciplinary team with extensive experience of developing and applying SBDD and FBDD methods
  • We pragmatically adapt and apply the most effective methods
    • Extensive use of biophysical methods to validate fragment binding
    • Developed new NMR and SPR methods for fragment evolution
  • We have extensive experience in tackling challenging targets
    • Success with difficult targets e.g. protein-protein interactions
    • Rapid assessment of the potential of targets for drug discovery

Continuing research collaborations with major pharmaceutical companies endorse our strengths.  Vernalis scientists are influential world figures in fragment-based discovery, speaking regularly at major conferences and with many widely cited publications.

Latest News

Results Announcement for the year ended 30 June 2017

Vernalis plc (LSE: VER) today announces its audited financial results for the year ended 30 June 2017, following the year-end trading update published on 18 July 2017.

Read more ...

Product Pipeline

For more information on our pipeline, click below to visit Vernalis plc

Commercial Pipeline

Comm-thumbnailExplore the pipeline ...


NCE Pipeline

NCE-thumbnailExplore the pipeline ...


Contact Vernalis Research

T: (0)1223 895555
F: (0)1223 895556

Contact information
Maps and directions
Contact form

Fact Sheet

For more information on Vernalis, click on the below image to download a copy of our fact sheet

Vernalis Factsheet May 2015 Page 1